New triple attack on tough colon cancer shows promise
NCT ID NCT04017650
Summary
This study is testing a combination of three drugs (encorafenib, cetuximab, and nivolumab) for people with advanced colorectal cancer that has a specific BRAF gene mutation and has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the three drugs work better together than standard treatments to control the cancer. It is for adults whose cancer has progressed after one or two prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III COLORECTAL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.